Literature DB >> 11489244

The role of resection for patients with renal carcinoma.

R C Flanigan1, P M Yonover.   

Abstract

Metastatic renal cancer is responsive in some cases to immunotherapeutic agents. Indications for nephrectomy in the face of metastatic disease have traditionally included palliation of symptoms caused by the primary tumor, and nephrectomy combined with metastatectomy in patients with resectable metastases. Recent findings from a Southwest Oncology Group trial strongly suggest that cytoreductive nephrectomy, combined with immunotherapy, may also result in improved survival in patients with unresectable metastases.

Entities:  

Mesh:

Year:  2001        PMID: 11489244     DOI: 10.1007/s11912-001-0029-0

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  41 in total

Review 1.  Role of surgery in patients with metastatic renal cell carcinoma.

Authors:  R C Flanigan
Journal:  Semin Urol Oncol       Date:  1996-11

2.  The surgical management of renal cell carcinoma.

Authors:  D G Skinner; C D Vermillion; R B Colvin
Journal:  J Urol       Date:  1972-05       Impact factor: 7.450

3.  Surgery following response to interferon-alpha-based therapy for residual renal cell carcinoma.

Authors:  A Sella; D A Swanson; J Y Ro; J B Putnam; R J Amato; A B Markowitz; C J Logothetis
Journal:  J Urol       Date:  1993-01       Impact factor: 7.450

Review 4.  Cancer immunotherapy: an overview.

Authors:  D L Morton
Journal:  Semin Oncol       Date:  1974-12       Impact factor: 4.929

Review 5.  Prognostic factors in renal cancer.

Authors:  J B Thrasher; D F Paulson
Journal:  Urol Clin North Am       Date:  1993-05       Impact factor: 2.241

6.  Long-term results of resection of renal cell cancer with extension into inferior vena cava.

Authors:  J A Libertino; L Zinman; E Watkins
Journal:  J Urol       Date:  1987-01       Impact factor: 7.450

7.  Surgeon's role in the management of solitary renal cell carcinoma metastases occurring subsequent to initial curative nephrectomy: an institutional review.

Authors:  P C Kierney; J A van Heerden; J W Segura; A L Weaver
Journal:  Ann Surg Oncol       Date:  1994-07       Impact factor: 5.344

8.  Infarction-nephrectomy for metastatic renal carcinoma. Southwest oncology group study.

Authors:  J E Gottesman; E D Crawford; H B Grossman; P Scardino; J D McCracken
Journal:  Urology       Date:  1985-03       Impact factor: 2.649

9.  Cytoreductive surgery prior to interleukin-2-based therapy in patients with metastatic renal cell carcinoma.

Authors:  M M Walther; R B Alexander; G H Weiss; D Venzon; A Berman; H I Pass; W M Linehan; S A Rosenberg
Journal:  Urology       Date:  1993-09       Impact factor: 2.649

10.  Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial.

Authors:  R I Fisher; C A Coltman; J H Doroshow; A A Rayner; M J Hawkins; J W Mier; P Wiernik; J D McMannis; G R Weiss; K A Margolin
Journal:  Ann Intern Med       Date:  1988-04       Impact factor: 25.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.